Abiraterone, a new treatment for advanced prostate cancer
Abiraterone is a drug discovered at The Institute of Cancer Research (ICR) which has been shown in clinical trials to extend life for men with late-stage prostate cancer.
Following more than two decades of dedicated work, in 2011 the drug was approved in the US and Europe for men with metastatic advanced prostate cancer.
